The team plans to further evaluate the nanomaterial against multiple cancer types. Oregon, US: Researchers at Oregon State University (OSU) have made a major breakthrough in cancer therapy with the development of a new nanomaterial that can selectively kill cancer cells while sparing healthy tissues. Unlike conventional chemodynamic therapy (CDT), which typically produces either hydroxyl radicals or singlet oxygen and often lacks sufficient catalytic activity, the new nanomaterial can generate both ROS types simultaneously, significantly enhancing therapeutic efficiency. The team plans to further evaluate the nanomaterial against multiple cancer types, including aggressive pancreatic cancer, to confirm its broad applicability across various malignancies before human clinical trials. This discovery marks a significant step forward in safer and more effective cancer treatment, potentially transforming the future of chemodynamic therapy.